Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer

Autor: Nina Kovačević, Nikola Besic, Eva Drmota, Sebastjan Merlo
Rok vydání: 2021
Předmět:
Adult
medicine.medical_specialty
medicine.medical_treatment
R895-920
Kaplan-Meier Estimate
Carcinoma
Ovarian Epithelial
Gastroenterology
Medical physics. Medical radiology. Nuclear medicine
03 medical and health sciences
0302 clinical medicine
Internal medicine
Preoperative Care
tumour marker
Humans
Medicine
Radiology
Nuclear Medicine and imaging
In patient
030212 general & internal medicine
Stage (cooking)
Aged
Retrospective Studies
Aged
80 and over
Ovarian Neoplasms
Analysis of Variance
Chemotherapy
Chi-Square Distribution
business.industry
Standard treatment
Advanced stage
Cancer
Cytoreduction Surgical Procedures
Middle Aged
medicine.disease
Debulking
Neoadjuvant Therapy
Progression-Free Survival
Treatment Outcome
ovarian cancer
Oncology
Chemotherapy
Adjuvant
CA-125 Antigen
030220 oncology & carcinogenesis
Female
primary debulking surgery
business
Ovarian cancer
ca-125
Research Article
neoadjuvant chemotherapy
Zdroj: Radiology and Oncology, Vol 55, Iss 3, Pp 341-346 (2021)
Radiology and Oncology
ISSN: 1581-3207
Popis: Background Ovarian cancer is the seventh most common cancer in women worldwide and the eighth most common cause of cancer death. Due to the lack of effective early detection strategies and the unspecific onset of symptoms, it is diagnosed at an advanced stage in 75% of cases. The cancer antigen (CA) 125 is used as a prognostic marker and its level is elevated in more than 85% of women with advanced stages of epithelial ovarian cancer (EOC). The standard treatment is primary debulking surgery (PDS) followed by adjuvant chemotherapy (ACT), but the later approach is neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). Several studies have been conducted to find out whether preoperative CA-125 serum levels influence treatment choice, surgical resection and survival outcome. The aim of our study was to analyse experience of single institution as Cancer comprehensive center with preoperative usefulness of CA-125. Patients and methods At the Institute of Oncology Ljubljana a retrospective analysis of 253 women with stage FIGO IIIC and IV ovarian cancer was conducted. Women were divided into two groups based on their primary treatment. The first group was the NACT group (215 women) and the second the PDS group (38 women). The differences in patient characteristics were compared using the Chi-square test and ANOVA and the Kaplan-Meier method was used for calculating progression-free survival (PFS) and overall survival (OS). Results The median serum CA-125 level was higher in the NACT group than in the PDS group, 972 IU/ml and 499 IU/ ml, respectively. The PFS in the NACT group was 8 months (95% CI 6.4–9.5) and 18 months (95% CI 12.5–23.4) in the PDS group. The median OS was lower in the NACT group than in the PDS group, 25 months (95% CI 20.6–29.5) and 46 months (95% CI 32.9–62.1), respectively. Conclusions Preoperative CA-125 cut off value of 500 IU/ml is a promising threshold to predict a successful PDS.
Databáze: OpenAIRE
Externí odkaz: